Q3 Results Reinforce Concerns: CyPath Growth Fails to Offset Revenue Decline and Widening Losses

What happened

bioAffinity's Q3 2026 results showed continued weakness in laboratory revenues, with losses widening despite strong growth in CyPath Lung test orders and physician adoption. The company's flagship test continues to gain traction, but the legacy pathology business decline and heavy commercialization spending are overwhelming the incremental CyPath contribution. This outcome aligns with the bear/base scenarios outlined in the prior analysis, which projected that CyPath would not scale quickly enough to offset consolidated revenue declines and high cash burn. The company had only about $2.6 million in net proceeds from its June 2026 financing, and with a quarterly operating cash burn likely still exceeding $3 million, liquidity remains extremely tight. Investors had hoped Q3 would mark a turning point, but the results suggest the company remains in survival mode, with further dilution likely if adoption does not accelerate sharply.

Implication

For investors, the key takeaway is that CyPath Lung's adoption, while real, is not yet sufficient to change the company's financial trajectory, and the Q3 report likely confirms that the path to profitability is longer than the market hoped. The failure of consolidated revenue to recover and the widening losses suggest that the company's decision to exit low-margin pathology services has not yet been offset by CyPath growth, leaving the business with less revenue to cover fixed costs. Given the cash position after the June raise, the company may need to raise additional capital within the next two to three quarters, which would likely be highly dilutive at the current depressed share price. The next critical catalysts are Q4 results and any announcements of institutional contracts (e.g., VA/DoD, health systems) that could signal a step-change in revenue, but until such evidence emerges, the risk-reward remains unfavorable. Investors should maintain a wait-and-see approach, with a re-assessment window of three to six months, and only consider building a position if the company demonstrates sustained CyPath revenue growth above $500K per quarter, consolidated revenue growth, and a meaningful reduction in cash burn.

Thesis delta

The Q3 report does not alter the core thesis but reinforces the bearish lean. The prior WAIT rating was based on insufficient evidence that CyPath could outgrow dilution, and Q3 provides another data point confirming that the company remains at high risk of needing further capital. No upgrade is warranted; the thesis remains unchanged.